Related Experiment Video
Updated: May 12, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Statistical design and data analysis for the effect of multiple doses of a treatment on renal functions using a
1Division of Biometrics VI, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Abstract:
Normally, the safety evaluation starts at a phase 1 study using healthy subjects, since the main purpose of phase 1 studies is to find out maximum tolerated doses and side effects. Sometimes, a multiple-dose study may be necessary to further understand the side effects of a treatment, since a specific side effect has been identified during the post-market safety evaluation after drugs are repeatedly administered to patients for treating a disease for a long time. Particularly, Phase 1 trial of interest here evaluates the effect of multiple doses of a drug on a renal function via measurement of a metabolite clearance in healthy subjects. In general, we know that the renal function will be adversely impaired by the drug intake. We propose a non-inferiority analysis allowing a small decrease in the renal function after the drug is taken. In this study, we discuss the design, power and sample size, and statistical data analysis.
Related Concept Videos
Bioavailability Study Design: Single Versus Multiple Dose Studies
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Analysis of Population Pharmacokinetic Data
Measurement of Bioavailability: Pharmacodynamic Methods
Dosage Regimens: Partial Pharmacokinetic Parameters
